

Council; Diabetes, Endocrinology and Metabolic Diseases Subcommittee.

Date: May 12–13, 2021.

Open: May 13, 2021, 10:00 a.m. to 11:30 a.m.

Agenda: To review the Division's scientific and planning activities.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

Closed: May 13, 2021, 11:45 a.m. to 1:15 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Karl F. Malik, Ph.D., Director Division of Extramural Activities, National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Boulevard, Room 7329, MSC 5452, Bethesda, MD 20892 (301) 594–4757, malikk@niddk.nih.gov.

Name of Committee: National Diabetes and Digestive and Kidney Diseases Advisory Council; Digestive Diseases and Nutrition Subcommittee.

Date: May 12–13, 2021.

Open: May 13, 2021, 10:00 a.m. to 11:30 a.m.

Agenda: To review the Division's scientific and planning activities.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

Closed: May 13, 2021, 11:45 a.m. to 1:15 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Karl F. Malik, Ph.D., Director Division of Extramural Activities, National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Boulevard, Room 7329, MSC 5452 Bethesda, MD 20892, (301) 594–4757 malikk@niddk.nih.gov.

Name of Committee: National Diabetes and Digestive and Kidney Diseases Advisory Council; Kidney, Urologic and Hematologic Diseases Subcommittee.

Date: May 12–13, 2021.

Open: May 13, 2021, 10:00 a.m. to 11:30 a.m.

Agenda: To review the Division's scientific and planning activities.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

Closed: May 13, 2021, 11:45 a.m. to 1:15 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Karl F. Malik, Ph.D., Director Division of Extramural Activities,

National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Boulevard, Room 7329, MSC 5452, Bethesda, MD 20892, (301) 594–4757, malikk@niddk.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: www.niddk.nih.gov/fund/divisions/DEA/Council/coundesc.htm, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: December 18, 2020.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020–28524 Filed 12–23–20; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of an Exclusive Patent License: Use of A CD47 Phosphorodiamidate Morpholino Oligomer for the Treatment, Prevention, and Diagnosis Of Cancer

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Morphix Biotherapeutics ("Morphix") located in Boston, MA.

DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before January 12, 2021 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Jaime M. Greene, Senior

Licensing and Patenting Manager at greenajaime@mail.nih.gov.

SUPPLEMENTARY INFORMATION:

Intellectual Property

- U.S. Provisional Patent Application No. 60/850,132, filed October 6, 2006, now abandoned (HHS Ref. No. E–227–2006–0–US–01);
- U.S. Provisional Patent Application No. 60/864,153, filed November 02, 2006, now abandoned (HHS Ref. No. E–227–2006–1–US–01);
- U.S. Provisional Patent Application No. 60/888,754, filed February 07, 2007, now abandoned (HHS Ref. No. E–227–2006–2–US–01);
- U.S. Provisional Patent Application No. 60/910,549, filed April 06, 2007, now abandoned (HHS Ref. No. E–227–2006–3–US–01);
- U.S. Provisional Patent Application No. 60/956,375, filed August 16, 2007, now abandoned (HHS Ref. No. E–227–2006–4–US–01);
- PCT Patent Application No. PCT/2007/080647, filed October 5, 2007, now abandoned (HHS Ref. No. E–227–2006–5–PCT–01);
- U.S. Patent No. 8,236,313, filed April 3, 2009, issued August 7, 2012 (HHS Ref. No. E–227–2006–5–US–02);
- Canadian Patent Application No. 2,665,287, October 5, 2007 (HHS Ref. No. E–227–2006–5–CA–03);
- Australian Patent No. 2007319576, filed October 5, 2007, issued May 1, 2014 (HHS Ref. No. E–227–2006–5–AU–04);
- European Patent No. 2076537, filed March 27, 2009, issued August 22, 2018 (HHS Ref. No. E–227–2006–5–EP–05);
- U.S. Patent Application No. 13/546,931, filed July 11, 2012 (HHS Ref. No. E–227–2006–5–US–06);
- U.S. Patent Number 8,557,788, filed July 11, 2012, issued October 15, 2013 (HHS Ref. No. E–227–2006–5–US–07);
- European Patent No. 2695896, filed October 5, 2007, issued August 22, 2018 (HHS Ref. No. E–227–2006–5–EP–08);
- Australian Patent No. 2014201936, filed April 4, 2014, issued October 20, 2016 (HHS Ref. No. E–227–2006–5–AU–09);
- U.S. Patent No. 10370439, filed September 29, 2014, issued August 6, 2019 (HHS Ref. No. E–227–2006–5–US–10);
- Australian Patent No. 2016238894, filed October 6, 2016, issued February 22, 2018 (HHS Ref. No. E–227–2006–5–AU–11);
- Australian Patent No. 2018200921, filed February 8, 2018, issued September 24, 2020 (HHS Ref. No. E–227–2006–5–AU–12)

- European Patent Application No. 18183780.8, filed July 16, 2018 (HHS Ref. No. E-227-2006-5-EP-13);
 - German Patent No. 2076537, issued August 22, 2018, filed March 27, 2009 (HHS Ref. No. E-227-2006-5-DE-14);
 - French Patent No. 2076537, issued August 22, 2018, filed March 27, 2009 (HHS Ref. No. E-227-2006-5-FR-15);
 - United Kingdom Patent No. 2076537, issued August 22, 2018, filed March 27, 2009 (HHS Ref. No. E-227-2006-5-GB-16);
 - German Patent No. 2695896, issued August 22, 2018, filed October 5, 2007 (HHS Ref. No. E-227-2006-5-DE-17);
 - French Patent No. 2695896, issued August 22, 2018, filed October 5, 2007 (HHS Ref. No. E-227-2006-5-FR-18);
 - United Kingdom Patent No. 2695896, issued August 22, 2018, filed October 5, 2007 (HHS Ref. No. E-227-2006-5-GB-19);
 - U.S. Patent Application No. 16/443,415, filed June 17, 2019 (HHS Ref. No. E-227-2006-5-US-20);
 - Australia Patent Application No. 2020230283, filed September 10, 2020 Pending (HHS Ref. No. E-227-2006-5-AU-21);
 - Provisional Patent Application No. 61/621,994, filed April 9, 2012, now abandoned (HHS Ref. No. E-086-2012-0-US-01);
 - Provisional Patent Application No. 61/735,701, filed December 11, 2012, now abandoned (HHS Ref. No. E-086-2012-1-US-01);
 - PCT Patent Application No. PCT/US2013/035838, filed April 9, 2013, now abandoned (HHS Ref. No. E-086-2012-2-PCT-01);
 - Australian Patent No. 2013246040, issued March 14, 2019, filed April 9, 2013 (HHS Ref. No. E-086-2012-2-AU-02);
 - Canadian Patent No. 2869913, issued September 10, 2019, filed April 9, 2013 (HHS Ref. No. E-086-2012-2-CA-03); Start Printed Page 327
 - European Patent No. 2836591, filed April 9, 2013, issued June 6, 2018 (HHS Ref. No. E-086-2012-2-EP-04);
 - US Patent No. 10407665, issued September 10, 2019, filed October 2, 2014 (HHS Ref. No. E-086-2012-2-US-05);
 - German Patent No. 2836591, issued June 6, 2018, filed April 9, 2013 (HHS Ref. No. E-086-2012-2-DE-07);
 - French Patent No. 2836591, issued June 6, 2018, filed April 9, 2013 (HHS Ref. No. E-086-2012-2-FR-08);
 - United Kingdom Patent No. 2836591, issued June 6, 2018, filed April 9, 2013 (HHS Ref. No. E-086-2012-2-GB-09);
 - US Patent Application No. 16/521,251, filed July 24, 2019 (HHS Ref. No. E-086-2012-2-US-10);
 - Provisional Patent Application No. 61/086,991, filed August 7, 2008, now abandoned (HHS Ref. No. E-153-2008-0-US-01);
 - PCT Patent Application No. PCT/US2009/052902, filed August 5, 2009, now abandoned (HHS Ref. No. E-153-2008-0-PCT-02);
 - Australian Patent No. 2009279676, issued July 30, 2015, filed August 5, 2009 (HHS Ref. No. E-153-2008-0-AU-03);
 - Canadian Patent No. 2732102, issued January 2, 2018, filed August 5, 2009 (HHS Ref. No. E-153-2008-0-CA-04);
 - European Patent No. 2340034, filed August 5, 2009, issued January 27, 2016 (HHS Ref. No. E-153-2008-0-EP-05);
 - US Patent No. 8951527, issued February 10, 2015, filed February 3, 2011 (HHS Ref. No. E-153-2008-0-US-06);
 - German Patent No. 602009036069.8, issued January 27, 2016, filed August 5, 2009 (HHS Ref. No. E-153-2008-0-DE-07);
 - French Patent No. 2340034, issued January 27, 2016, filed August 5, 2009 (HHS Ref. No. E-153-2008-0-FR-08);
 - United Kingdom Patent No. 2340034, issued January 27, 2016, filed August 5, 2009 (HHS Ref. No. E-153-2008-0-GB-09);
 - Provisional Patent Application No. 61/779,587, filed March 13, 2013, now abandoned (HHS Ref. No. E-296-2011-0-US-01);
 - PCT Patent Application No. PCT/US2014/025989, filed March 13, 2014, now abandoned (HHS Ref. No. E-296-2011-0-PCT-02);
 - Australian Patent No. 2014244083, issued January 10, 2019, filed March 13, 2014, now abandoned (HHS Ref. No. E-296-2011-0-AU-03);
 - Canadian Patent Application No. 2905418, filed March 13, 2014 (HHS Ref. No. E-296-2011-0-CA-04);
 - European Patent Application No. 14718255.4, filed March 13, 2014 (HHS Ref. No. E-296-2011-0-EP-05);
 - US Patent Application No. 14/775,428, filed September 11, 2015 (HHS Ref. No. E-296-2011-0-US-06).
 - U.S. Provisional Patent Application No. 62/062,675, filed October 10, 2014, now abandoned (HHS Ref. No. E-263-2014-0-US-01);
 - PCT Patent Application No. PCT/US2015/055029, filed October 9, 2015, now abandoned (HHS Ref. No. E-263-2014-0-PCT-02);
 - Australia Patent Application No. 2015329696, filed October 9, 2015 (HHS Ref. No. E-263-2014-0-AU-03);
 - Canadian Patent Application No. 2964173, filed October 9, 2015 (HHS Ref. No. E-263-2014-0-CA-04);
 - European Patent No. 3204420, filed October 9, 2015, issued September 2, 2020 (HHS Ref. No. E-263-2014-0-EP-05);
 - U.S. Patent Application No. 15/517,345, filed April 6, 2017 (HHS Ref. No. E-263-2014-0-US-06);
 - German Patent No. 3204420, issued September 2, 2020, filed October 9, 2015 (HHS Ref. No. E-263-2014-0-DE-07);
 - French Patent No. 3204420, issued September 2, 2020, filed October 9, 2015 (HHS Ref. No. E-263-2014-0-FR-08);
 - United Kingdom Patent No. 3204420, issued September 2, 2020, filed October 9, 2015 (HHS Ref. No. E-263-2014-0-GB-09).
- The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.
- The prospective exclusive license territory may be worldwide and the field of use may be limited to the use of all of the above Licensed Patent Rights for the following: "The use of the CD47 phosphorodiamidate morpholino oligomers (PMO, morpholino, Sequence: 5'-CGTCACAGGCAGGACCCACTGCCCA-3'), in combination with radiotherapy, for the treatment, prevention, and diagnosis of cancer." For the Licensed Patent Rights encompassed by technologies with the HHS. Ref. No. starting with E-263-2014, the prospective exclusive license territory may be worldwide and the field of use may be limited to: "The use of the CD47 phosphorodiamidate morpholino oligomers (PMO, morpholino, Sequence: 5'-CGTCACAGGCAGGACCCACTGCCCA-3') for the treatment, prevention, and diagnosis of cancer."
- This technology concerns CD47, originally named integrin-associated protein, which is a receptor for thrombospondin-1 (TSP1), a major component of platelet α -granules from which it is secreted on platelet activation. A number of important roles for CD47 have been defined in regulating the migration, proliferation, and survival of vascular cells, and in regulation of innate and adaptive immunity. Nitric Oxide (NO) plays an important role as a major intrinsic vasodilator, and it increases blood flow to tissues and organs. Disruption of this process leads to peripheral vascular disease, ischemic heart disease, stroke, diabetes and many more significant diseases. The inventors have discovered that TSP1 blocks the beneficial effects of NO and prevents it from dilating blood vessels and increasing blood flow to organs and tissues. Additionally, they discovered that this regulation requires

TSP1 interaction with its cell receptor, CD47. These inventors have also found that blocking TSP1–CD47 interaction through the use of antisense morpholino oligonucleotides, peptides or antibodies have several therapeutic benefits including the treatment of cancer.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: December 17, 2020.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2020–28570 Filed 12–23–20; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Docket ID FEMA–2020–0002]

Final Flood Hazard Determinations

AGENCY: Federal Emergency Management Agency, DHS.

ACTION: Notice.

SUMMARY: Flood hazard determinations, which may include additions or modifications of Base Flood Elevations (BFEs), base flood depths, Special Flood Hazard Area (SFHA) boundaries or zone designations, or regulatory floodways on the Flood Insurance Rate Maps (FIRMs) and where applicable, in the supporting Flood Insurance Study (FIS) reports have been made final for the communities listed in the table below.

The FIRM and FIS report are the basis of the floodplain management measures that a community is required either to adopt or to show evidence of having in effect in order to qualify or remain qualified for participation in the Federal Emergency Management Agency's (FEMA's) National Flood Insurance Program (NFIP). In addition, the FIRM and FIS report are used by insurance agents and others to calculate appropriate flood insurance premium rates for buildings and the contents of those buildings.

DATES: The date of April 21, 2021 has been established for the FIRM and, where applicable, the supporting FIS report showing the new or modified flood hazard information for each community.

ADDRESSES: The FIRM, and if applicable, the FIS report containing the final flood hazard information for each community is available for inspection at the respective Community Map Repository address listed in the tables below and will be available online through the FEMA Map Service Center

at <https://msc.fema.gov> by the date indicated above.

FOR FURTHER INFORMATION CONTACT: Rick Sacbibit, Chief, Engineering Services Branch, Federal Insurance and Mitigation Administration, FEMA, 400 C Street SW, Washington, DC 20472, (202) 646–7659, or (email) patrick.sacbibit@fema.dhs.gov; or visit the FEMA Mapping and Insurance eXchange (FMIX) online at https://www.floodmaps.fema.gov/fhm/fmx_main.html.

SUPPLEMENTARY INFORMATION: The Federal Emergency Management Agency (FEMA) makes the final determinations listed below for the new or modified flood hazard information for each community listed. Notification of these changes has been published in newspapers of local circulation and 90 days have elapsed since that publication. The Deputy Associate Administrator for Insurance and Mitigation has resolved any appeals resulting from this notification.

This final notice is issued in accordance with section 110 of the Flood Disaster Protection Act of 1973, 42 U.S.C. 4104, and 44 CFR part 67. FEMA has developed criteria for floodplain management in floodprone areas in accordance with 44 CFR part 60.

Interested lessees and owners of real property are encouraged to review the new or revised FIRM and FIS report available at the address cited below for each community or online through the FEMA Map Service Center at <https://msc.fema.gov>.

The flood hazard determinations are made final in the watersheds and/or communities listed in the table below.

(Catalog of Federal Domestic Assistance No. 97.022, "Flood Insurance.")

Michael M. Grimm,

Assistant Administrator for Risk Management, Department of Homeland Security, Federal Emergency Management Agency.

Community	Community map repository address
Los Angeles County, California and Incorporated Areas	
Docket No.: FEMA-B-1716	
City of El Segundo	City Hall, 350 Main Street, El Segundo, CA 90245.
City of Hermosa Beach	City Hall, 1315 Valley Drive, Hermosa Beach, CA 90254.
City of Long Beach	City Hall, 333 West Ocean Boulevard, 9th Floor, Long Beach, CA 90802.
City of Los Angeles	Department of Public Works, 1149 South Broadway, Suite 810, Los Angeles, CA 90015.
City of Malibu	City Hall, 23825 Stuart Ranch Road, Malibu, CA 90265.
City of Manhattan Beach	Engineering Department, 3621 Bell Avenue, Manhattan Beach, CA 90266.
City of Palos Verdes Estates	City Hall, 340 Palos Verdes Drive West, Palos Verdes Estates, CA 90274.